Objectives: To assess the safety and efficacy of a dolutegravir-based regimen in perinatally HIV-1-infected adolescents.
Introduction
Achieving good adherence to treatment and viral suppression in the long term remains challenging in children and adolescents perinatally infected with HIV. Overall virological failure (VF) rates in this group are more than double those in adults, even in highresource countries. 1 Suboptimal virological suppression may lead to the selection of drug-resistant viruses, with particularly serious consequences in children likely to need ART for very long periods of time. Moreover, the number of paediatric formulations available for ART remains limited, preventing some children from receiving fully active combinations in cases of resistance to first-line regimens. Dolutegravir is a powerful, easy-to-take, well-tolerated integrase inhibitor (INI) for which there is a high genetic barrier to resistance and few drug-drug interactions have been reported. 2 Dolutegravir-based combinations are now approved for use in HIV-1-infected adolescents aged 12 years in many countries worldwide. However, few data have been published concerning the efficacy of dolutegravir in this population with a high risk of VF. 3 Moreover, a recent study in the real-life setting reported an unexpectedly high frequency of adult patients stopping dolutegravir treatment due to intolerance. 4 To our knowledge, this multicentre study provides the first data for dolutegravir safety and efficacy in adolescents perinatally infected with HIV-1 in real-life conditions.
Patients and methods
We conducted a retrospective, non-interventional study in three large paediatric care centres. We included all patients vertically infected with HIV-1 who: (i) began treatment with a dolutegravirbased regimen between January 2014 and December 2015; and (ii) had at least one determination of plasma viral load (PVL) available 3 months after dolutegravir initiation. If INI resistanceassociated mutations (RAMs) (other than isolated L74I polymorphic mutations) had previously been detected, the patients received 50 mg of dolutegravir twice daily. In all other cases, the adolescents received 50 mg of dolutegravir once daily.
All decisions to switch to dolutegravir were validated by the local HIV expert teams. Participants provided informed consent for the anonymous use of their clinical and biological data for biomedical research at the time of data collection.
We collected demographic characteristics, history of ART since birth, PVL history and CD4þ T cell count assessed during the 6 months preceding dolutegravir initiation (i.e. baseline). Virological suppression at baseline was defined as PVL <50 copies/mL for 6 months. All genotypic resistance tests performed since birth were analysed. Resistance to NRTI, NNRTI, PI and INI was defined according to the 2015 ANRS HIV-1 genotypic resistance interpretation algorithm v.25 (www.hivfrenchresistance.org). We estimated the genotypic susceptibility score (GSS) from the list of isolated RAMs. For all drugs, we translated the definitions 'susceptible', 'intermediate' and 'resistant' from the ANRS algorithm into susceptibility scores of 1, 0.5 and 0, respectively. The arithmetic sum of individual scores for each of the drugs considered provided the total treatment-related GSS, as previously described. 5 In patients with virological suppression who had not previously undergone integrase gene sequencing, INI resistance was evaluated by sequencing the integrase gene from PBMC-associated HIV-1 DNA. In cases of failure to amplify the integrase gene, the virus was considered fully susceptible to dolutegravir (score of 1) in INI-naive adolescents.
After dolutegravir initiation, the following data were collected: clinical events, PVL, CD4þ T cell count, results for routine plasma haematological and biochemical parameters, genotypic resistance tests at the time of VF (if any) and ART changes (if any). The adolescents were also questioned about their compliance with treatment at each follow-up visit.
The primary endpoint was the proportion of patients achieving PVL <50 copies/mL within 3 months of dolutegravir initiation (for patients with detectable viraemia at baseline) and displaying maintenance of virological suppression (PVL <50 copies/mL) until the last follow-up visit (for all patients). The primary endpoint was determined at 3 months, because in previous clinical trials, dolutegravir rapidly yielded virological suppression, at frequencies that were similar 12, 48 and 96 weeks after dolutegravir initiation. In adolescents with virological suppression at baseline, VF was defined as two consecutive determinations of PVL 50 copies/mL. Patient data were retained for analysis as long as the dolutegravir strategy was continued. Otherwise, they were censored at the time of treatment discontinuation. The secondary endpoint was safety (adverse effects, AIDS-related events and deaths). v 2 tests or Fisher's exact tests were used to compare discrete variables and the Wilcoxon rank test was used to compare continuous variables between patients with suppressed viraemia and patients with VF while on dolutegravir-based treatment. Analyses were performed with SAS 9.4 (SAS, Cary, NC, USA).
Results

Efficacy
Fifty adolescents vertically infected with HIV-1 were enrolled. Their characteristics are shown in Table 1 . Nine patients had previously received a raltegravir-containing regimen: three adolescents experienced VF on raltegravir (maximum viraemia level ¼ 316, 6400 and 1 600 000 copies/mL, respectively) and the other six patients displayed sustained viral suppression on a raltegravir-based combination. At baseline, 17/50 patients (34%) had displayed virological suppression for 6 months. For 14 (82%) of these patients, virological success was maintained on the dolutegravir-based combination. Three adolescents experienced a transient virological rebound, but PVL fell to < 50 copies/mL again during follow-up, with no change in ART regimen, after interventions to improve compliance with treatment. All patients with sustained virological suppression at baseline had undetectable viraemia at their last visit [median follow-up: 10 months (IQR: 6-12)].
Thirty-three patients began dolutegravir treatment after the detection of viraemia at baseline and/or during the previous 6 months. All but one had been treated with antiretroviral drugs before and two adolescents restarted ART after unplanned treatment interruptions of several months. Nineteen patients (58%) achieved virological suppression within 3 months of starting dolutegravir treatment, with the maintenance of virological success thereafter. Three additional viraemic adolescents had an undetectable PVL at the last visit, with no change in ART regimen, following interventions to improve compliance with treatment. In this group, virological suppression was recorded for 22/33 adolescents (67%) at the last visit [median follow-up: 9 months (IQR: 5-13)]. Eleven patients still had detectable viraemia at the last visit. Four of these patients had never displayed virological suppression, whereas the other seven had suffered viral rebound.
Six of the nine patients with prior raltegravir treatment displayed virological suppression at baseline. Three of these patients experienced VF on dolutegravir: transient viral rebound in two adolescents (with virological suppression at the last visit, with no need for a change in ART regimen) and viral rebound (80 000 copies/mL) at the last follow-up visit in one patient, who reported a decrease in compliance with ART 10 months after its initiation. The three Briand et al. (9) 9 (18) previous exposure to ELV/CBT, enfuvirtide or maraviroc, n (%) 
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Dolutegravir in perinatally HIV-1-infected adolescents JAC patients with prior raltegravir treatment and detectable viraemia at baseline experienced sustained viral suppression on the dolutegravir-based combination. Overall, virological success was observed in 66% of patients and viraemia was suppressed in 78% of the adolescents at the last visit. All adolescents with VF declared a decrease in compliance with ART during their follow-up visits. The subjects with VF were more likely than those with virological success to have been born in sub-Saharan African countries (94% versus 52%; P ¼ 0.004) and to have more frequently detectable viraemia on ART during the 6 months preceding dolutegravir initiation (82% versus 58%; P ¼ 0.03) ( Table 2 ). The two groups were similar in terms of sex, age, characteristics of the dolutegravir-based regimen (number of pills per day and dosing frequency) and the cumulative GSS of the ART combination.
Antiretroviral drug resistance
Cumulative GSS was determined in 44 patients at baseline. Major NRTI, NNRTI and PI resistance mutations were observed in 68%, 43% and 28% of cases, respectively (Table S1 , available as Supplementary data at JAC Online). The most frequent RAMs were M184V/I (61%), Y181C (20%) and thymidine analogue mutations (30%). The integrase gene was sequenced in all nine adolescents with a history of raltegravir treatment and in 21/41 INI-naive patients. INI RAMs were detected in two of the nine raltegravirexperienced patients: an isolated L74I mutation in a patient with sustained viral suppression on raltegravir; and an isolated N155H mutation in a subject with previous VF (maximum viraemia during raltegravir exposure: 6400 copies/mL). This last patient was treated with a regimen combining darunavir/ritonavir, tenofovir/emtricitabine and dolutegravir and achieved sustained virological success during follow-up. No INI RAMs were detected in the other seven adolescents with a history of raltegravir treatment, including two with a history of VF on raltegravir. INI RAMs were identified at baseline in 2/21 INI-naive subjects: an isolated L74I mutation in both cases.
Genotypic resistance was assessed in samples from all 17 subjects presenting VF during follow-up: 14 INI-naive patients, 2 raltegravir-experienced subjects with no prior detection of INI RAMs and 1 adolescent with a history of raltegravir treatment in whom an isolated L74I mutation had previously been detected. Median peak viraemia at VF was 3.8 log 10 copies/mL (IQR: 2.9-4.8).
Major mutations associated with resistance to NRTIs, NNRTIs and PIs were isolated before dolutegravir initiation in 12, 11 and 4 of these 17 cases, respectively. No selection of new RAMs in the reverse transcriptase, protease or integrase gene was observed in these 17 patients during exposure to dolutegravir (median followup: 6 months). Data for the three patients not taking ART at the time of dolutegravir initiation are not shown (one antiretroviral-naive patient and two adolescents who had stopped treatment for >6 months).
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Tolerance
Two patients (4%) experienced neurological side effects during follow-up: moderate headache and dizziness not necessitating treatment cessation in one case; and severe dizziness, sleeping disorders and anxiety, which resolved after dolutegravir interruption, in the other. No other grade 3 or 4 clinical or biological side effects were reported. No AIDS-related events or deaths occurred.
Discussion
We report here the largest ever study of the efficacy and tolerance of a dolutegravir-based regimen in adolescents perinatally infected with HIV-1. In patients with virological control before the initiation of the dolutegravir-based regimen, this regimen was generally introduced as a simplification strategy, to decrease the number of pills taken daily (2 pills/day in 70% of adolescents versus 35% previously) and/or the daily dosing frequency (once daily in 94% of patients versus 71% previously). Virological suppression was maintained in 82% of subjects and viraemia was suppressed in all patients at the last visit.
In patients with previously detectable viraemia, the efficacy profile of a combination of dolutegravir with an optimized background regimen (OBR) was similar to that reported in the IMPAACT P1093 study, with 58% (versus 61% in the IMPAACT study) of participants achieving and maintaining PVL <50 copies/mL. 3 This frequency is slightly lower than that obtained in the SAILING study, 6 Some baseline characteristics were similar in our patients and in the subjects receiving dolutegravir in the SAILING trial: there was a high proportion of INI-naive patients (82% versus 100%), a low rate of hepatitis coinfection (0% versus 14%) and similar numbers of previous courses of ART received (four versus five). However, seven main differences were observed between our patients and those included in the SAILING trial: a higher proportion of black patients (89% versus 40%), a lower baseline PVL (1.8 versus 4.2 log 10 copies/mL), a higher baseline CD4þ T cell count (633 versus 205 per mm 3 ), a longer duration of previous exposure to ART (12.8 years versus 80 months), a higher proportion of patients with a GSS >2 (36% versus <1%), a lower frequency of PI-containing background regimens (24% versus 85%) and younger patients (18 versus 42 years). The difference between the rates of viral suppression observed in the SAILING trial and our study reflect the characteristically poor compliance with treatment of perinatally infected adolescents.
1 Indeed, 82% of the patients with VF on dolutegravir had experienced VF during the 6 months before dolutegravir initiation. Moreover, the cumulative GSS for the dolutegravir-based combination was similar in adolescents with VF and those with virological success. Our results support the view that measures are required to improve compliance in perinatally infected adolescents undergoing treatment changes, including simplification strategies. In our study, such measures increased the rate of viral suppression from 66% to 78% at the end of follow-up, without the need for a change in ART regimen.
Three of the nine patients previously treated with raltegravir experienced VF on dolutegravir. The viral rebound was transient in two cases. In both cases, viraemia was undetectable at the last visit, without any change in ART regimen, following interventions to improve compliance with treatment. In the remaining case, INI resistance was evaluated by sequencing the integrase gene from PBMC-associated HIV DNA at baseline, which revealed an isolated L74I mutation. The patient experienced viral rebound at his last follow-up visit and reported a decrease in compliance with ART. No other INI RAM was detected in this patient. Thus, although we cannot exclude that more sensitive genotyping might have revealed additional INI RAMs in raltegravir-experienced patients, the virological follow-up of these patients suggests that the occurrence of viral rebound was probably related to a decrease in compliance with ART rather than an accumulation of INI RAMs, which would have decreased the efficacy of dolutegravir.
Dolutegravir was safe and treatment had to be stopped in only one case (2%), due to drug-related neurological side effects. This low rate of severe drug-related adverse events is similar to those reported in previous trials in adults [6] [7] [8] and adolescents, 3 but lower than that reported in a recent study in a real-life setting, in which 16% of adults stopped taking dolutegravir due to intolerance.
